Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series

被引：2
|
作者：
Horiuchi, Kazuhiro [1 ]
Nakamura, Shuntaro [1 ]
Yamada, Kazuki [1 ]
Inoue, Takashi [1 ]
Oiwa, Kei [1 ]
机构：
[1] Hakodate Municipal Hosp, Dept Neurol, Hakodate, Japan
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 39卷
关键词：
Myasthenia gravis; Neonatal Fc receptor; Activities of daily; Living; Corticosteroids; Efgartigimod; FcRn antagonist; DOUBLE-BLIND;
D O I：
10.1016/j.nmd.2024.04.005
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The effect of treatment with efgartigimod in seronegative myasthenia gravis (MG) remains unclear. This retrospective study aimed to evaluate symptomatic changes and safety of treatment with efgartigimod in patients with generalized MG (gMG) double-seronegative for acetylcholine receptor antibody and muscle-specific kinase antibody. We reviewed the medical records of double-seronegative gMG treated with 10 mg/kg efgartigimod once/week per cycle (4 weeks) from June 2022 to June 2023. A total of 16 patients were included. MG-activities of daily living (ADL) scores improved from 9.2 to 7.4. Mean prednisolone dose was reduced from 5.4 to 4.1 mg/day. The duration before MG-ADL deterioration after the end of a cycle was 6.1 weeks. Five patients had mild adverse events. This retrospective study revealed no significant treatment benefit in the outcomes of patients with double-seronegative gMG treated with efgartigimod. (c) 2024 Elsevier B.V. All rights reserved.
引用
收藏
页码：37 / 41
页数：5
相关论文
共 50 条
  • [31] A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England
    van Enkhuizen, Jordy
    Binns, Jean
    Betts, April
    Hosnijeh, Fatemeh Saberi
    Alexander, Myriam
    McCormack, Mark
    Jacob, Saiju
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [32] Clinical remission of moderate generalized myasthenia gravis through exclusive use of Buzhong Yiqi decoction: A case report
    Qiu, Hui
    Chen, Xinru
    Zhang, Liping
    Zhang, Qing
    Qiu, Changlin
    Li, Jingya
    EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2024, 20 (04) : 588 - 591
  • [33] Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)
    Sacca, Francesco
    Barnett, Carolina
    Vu, Tuan
    Peric, Stojan
    Phillips, Glenn A.
    Zhao, Sihui
    Qi, Cynthia Z.
    Gelinas, Deborah
    Chiroli, Silvia
    Verschuuren, Jan J. G. M.
    JOURNAL OF NEUROLOGY, 2023, 270 (04) : 2096 - 2105
  • [34] Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)
    Francesco Saccà
    Carolina Barnett
    Tuan Vu
    Stojan Peric
    Glenn A. Phillips
    Sihui Zhao
    Cynthia Z. Qi
    Deborah Gelinas
    Silvia Chiroli
    Jan J. G. M. Verschuuren
    Journal of Neurology, 2023, 270 : 2096 - 2105
  • [35] Thymectomy in severe (Myasthenia Gravis Foundation of America classes IV-V) generalized myasthenia gravis: is the game really worth the candle? A retrospective analysis from a multi-institutional database
    Brascia, Debora
    Lucchi, Marco
    Aprile, Vittorio
    Guida, Melania
    Ricciardi, Roberta
    Rea, Federico
    Comacchio, Giovanni Maria
    Schiavon, Marco
    Marino, Maria Carlotta
    Margaritora, Stefano
    Meacci, Elisa
    Spagni, Gregorio
    Evoli, Amelia
    Lorenzoni, Giulia
    De Iaco, Giulia
    De Palma, Angela
    Marulli, Giuseppe
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2023, 63 (05)
  • [36] Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study
    Ruan, Zhe
    Huan, Xiao
    Su, Yue
    Tang, Yong-Lan
    Meng, Dong-Dong
    Ren, Da-Lin
    Li, Chun-Hong
    Hao, Si-Jia
    Zhao, Chong-Bo
    Luo, Su-Shan
    Li, Zhu-Yi
    Chang, Ting
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [37] A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
    Howard, James F., Jr.
    Barohn, Richard J.
    Cutter, Gary R.
    Freimer, Miriam
    Juel, Vern C.
    Mozaffar, Tahseen
    Mellion, Michelle L.
    Benatar, Michael G.
    Farrugia, Maria Elena
    Wang, Jing Jing
    Malhotra, Suneil S.
    Kissel, John T.
    MUSCLE & NERVE, 2013, 48 (01) : 76 - 84
  • [38] Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
    Murai, Hiroyuki
    Suzuki, Shigeaki
    Hasebe, Miki
    Fukamizu, Yuji
    Rodrigues, Ema
    Utsugisawa, Kimiaki
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [39] Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series
    Levine, Todd D.
    AMERICAN JOURNAL OF CASE REPORTS, 2019, 20 : 965 - 970
  • [40] Therapeutic Effect and Side Effects of Pharmacotherapy in Patients With Parkinson Disease and Myasthenia Gravis: A Systematic Review of Case Reports and Case Series Studies
    Xie, Haoyu
    Liu, Yadi
    Schmidt, Cindy
    Chien, Jung Hung
    Wang, Chuhuai
    CLINICAL THERAPEUTICS, 2024, 46 (03) : 275 - 284
12345